This National Institute for Health and Care Excellence (NICE) guideline covers assessing and reducing the risk of venous thromboembolism (VTE or blood clots) and deep vein thrombosis (DVT) in people aged 18 and over in hospital. It aims to help healthcare professionals identify people most at risk of VTE. It describes treatments and interventions that can be used to prevent VTE.
 Prescribers should consult the summary of product characteristics for the pharmacological VTE prophylaxis being used or planned for further details.
 At the time of publication (June 2015) some types of LMWH do not have UK marketing authorisation for VTE prophylaxis in medical patients. Prescribers should consult the summary of product characteristics for the individual LMWH. Informed consent for off‑label use should be obtained and documented.
VTE is an important cause of death in hospital patients, and treatment of non‑fatal symptomatic VTE and related long‑term morbidities is associated with considerable cost to the health service.
The risk of developing VTE depends on:
This guideline makes recommendations on assessing and reducing the risk of VTE in patients in hospital. It offers guidance on the most clinically and cost‑effective measures for VTE prophylaxis in these patients. The recommendations take into account the potential risks of the various options for prophylaxis and patient preferences.
You can read the guideline on NICE's website.